Longevity & AgingNew Obesity Drug Ribupatide Achieves 12% Weight Loss in Phase 2 Oral Trial
Ribupatide, a new dual GLP-1/GIP receptor drug being developed as both a daily pill and weekly injection, produced up to 12% body weight loss in a Phase 2 trial. Tested in 166 adults with obesity in China, the 25mg and 50mg oral doses both hit 12.1% mean weight loss at 26 weeks, compared to 2.3% for placebo. Nearly 60% of participants on the 25mg dose lost at least 10% of their body weight. Side effects were mild to moderate gastrointestinal issues, consistent with other GLP-1 drugs like semaglutide. An NDA has been filed in China, and global Phase 3 trials are planned for 2027, positioning ribupatide as a potential new entrant in the rapidly expanding obesity drug market.
